Tarsier Pharma
Tarsier Pharma is a late clinical-stage Israeli pharmaceutical company developing treatments for autoimmune and inflammatory ocular diseases, particularly panuveitis. Led by founder-CEO Daphne Haim-Langford, the Haifa-based firm filed for a proposed NYSE IPO in 2026.
- Company typePrivate
- Founded2016
- HeadquartersHaifa, Israel
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What Tarsier Pharma does
Tarsier Pharma is a late clinical-stage pharmaceutical company headquartered in Haifa, Israel, focused on developing treatments for autoimmune and inflammatory ocular diseases, with an emphasis on the panuveitis treatment market. Founded in 2016, the company operates with a lean team of 1-10 employees and is led by founder and CEO Daphne Haim-Langford, supported by COO Zohar Milman and VP of Clinical Affairs Emilee Fulcher. The specific product portfolio, candidate molecule names, mechanism of action, and clinical trial details are not disclosed in available sources.
The company has historically funded its operations through a combination of strategic and non-dilutive capital, including a $3 million investment from Sun Pharmaceutical in September 2018 and a $2.4 million Horizon 2020 grant in September 2019, bringing total disclosed funding to approximately $5.4 million. Tarsier Pharma remains a privately held company but filed for a proposed initial public offering on the New York Stock Exchange on April 21, 2026, signaling an intent to broaden its capital base ahead of further clinical or commercial milestones. The company does not yet generate product revenue and operates in a global panuveitis treatment market estimated at $4.31 billion in 2025 and projected to reach $10.68 billion by 2035 at a 9.5% CAGR.
As a pre-commercial biotech, Tarsier Pharma's business model is currently anchored on R&D execution, clinical development, and capital formation rather than recurring product sales. Pricing, go-to-market strategy, and patient access pathways have not been disclosed, consistent with an asset that has not yet reached regulatory approval or commercialization. The proposed US listing represents the most significant strategic inflection point to date and is likely intended to finance pivotal trials, regulatory submissions, and eventual market entry in autoimmune and inflammatory ocular disease indications.
Tarsier Pharma firmographics
Firmographics- Name
- Tarsier Pharma
- Website
- https://tarsiuspharma.com
- Company type
- Private
- Founded year
- 2016
- Operating status
- Ipo
- Headcount range
- 11–50 employees
- Short description
- Tarsier Pharma is a late clinical-stage Israeli pharmaceutical company developing treatments for autoimmune and inflammatory ocular diseases, particularly panuveitis. Led by founder-CEO Daphne Haim-Langford, the Haifa-based firm filed for a proposed NYSE IPO in 2026.
- Ownership category
- akta.pro rank
Tarsier Pharma industry classification
Industry- Product category
- Ophthalmic Pharmaceuticals
- NAICS
- Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Primary Care & General Medicine Pharmaceuticals (HLAIAAAA)
- akta.pro secondary industry
- Clinical Trial Pharmacy & IMP Management at Site (HLAGACAK)
Keywords
Where Tarsier Pharma is headquartered
LocationHeadquarters
- HQ city
- Haifa
- HQ country
- Israel
- HQ region
- Middle East
Markets served
Tarsier Pharma business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations
Tarsier Pharma product offering
Product offeringCore offering
Tarsier Pharma is a late clinical-stage pharmaceutical company that develops therapeutic treatments for autoimmune and inflammatory ocular diseases, with a specific focus on panuveitis. The company has not yet launched a commercial product, and its website was inaccessible at the time of data collection. It is preparing for a public listing on the New York Stock Exchange.
Product overview
Tarsier Pharma is a pharmaceutical company operating in the panuveitis treatment market, with an IPO filing pending on the NYSE. The available source data does not provide details on the company's specific product portfolio, product names, or service offerings.
Differentiator
Problem solved
Functional benefit
Companies that use Tarsier Pharma
Customer profileIdeal customer profiles1 record
Tarsier Pharma technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Tarsier Pharma partnerships and signals
Strategic signalScale indicators2 records
Recent moves4 records
Expansion highlights3 records
Tarsier Pharma competitors and assessment
Company assessmentMarket position
Competitive moat3 records
Key highlights6 records
Customer concentration
Tarsier Pharma social profiles
Digital presenceTarsier Pharma financial estimates
Financial estimateRevenue estimate
Valuation estimate
Tarsier Pharma leadership team
Management profileNumber of profiles
Profiles3 records
Tarsier Pharma funding detail
Funding detailFunding overview
Funding rounds2 records
Investors2 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Tarsier Pharma M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Tarsier Pharma
What does Tarsier Pharma do?
Tarsier Pharma is a late clinical-stage pharmaceutical company that develops therapeutic treatments for autoimmune and inflammatory ocular diseases, with a specific focus on panuveitis. The company has not yet launched a commercial product, and its website was inaccessible at the time of data collection. It is preparing for a public listing on the New York Stock Exchange.
Is Tarsier Pharma a public or private company?
Tarsier Pharma is a private company. It is classified as venture growth investor backed and is currently ipo.
When was Tarsier Pharma founded?
Tarsier Pharma was founded in 2016. It employs 11 to 50 people.
Where is Tarsier Pharma based?
Tarsier Pharma is headquartered in Haifa, Israel, in the Middle East region.
Does Tarsier Pharma have an API?
No public API is recorded for Tarsier Pharma.
What industry is Tarsier Pharma in?
Tarsier Pharma's product category is Ophthalmic Pharmaceuticals. Its primary akta.pro industry code is HLAIAAAA, Primary Care & General Medicine Pharmaceuticals, with a secondary code of HLAGACAK, Clinical Trial Pharmacy & IMP Management at Site. Its NAICS code is 325412 and its SIC code is 2834.